Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment.

MLA

Courlet, Perrine, et al. “Escitalopram Population Pharmacokinetics in People Living with Human Immunodeficiency Virus and in the Psychiatric Population: Drug–drug Interactions and Probability of Target Attainment.” British Journal of Clinical Pharmacology, vol. 85, no. 9, Sept. 2019, pp. 2022–32. EBSCOhost, https://doi.org/10.1111/bcp.13994.

APA

Courlet, P., Guidi, M., Glatard, A., Alves Saldanha, S., Cavassini, M., Buclin, T., Marzolini, C., Eap, C. B., Decosterd, L. A., & Csajka, C. (2019). Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment. British Journal of Clinical Pharmacology, 85(9), 2022–2032. https://doi.org/10.1111/bcp.13994

Chicago

Courlet, Perrine, Monia Guidi, Anaïs Glatard, Susana Alves Saldanha, Matthias Cavassini, Thierry Buclin, Catia Marzolini, Chin B. Eap, Laurent A. Decosterd, and Chantal Csajka. 2019. “Escitalopram Population Pharmacokinetics in People Living with Human Immunodeficiency Virus and in the Psychiatric Population: Drug–drug Interactions and Probability of Target Attainment.” British Journal of Clinical Pharmacology 85 (9): 2022–32. doi:10.1111/bcp.13994.